Q-omics provides the consensus-scored MIR579 profile across patient tissues and cancer cell-line models. MIR579 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR579 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, MIR579 RNA expression shows 13,860 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, LUAD, and THYM as cancer lineages where MIR579 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR579 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR579 survival associations across molecular data types. MIR579 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR579 RNA expression–survival associations across cancer types. High MIR579 expression shows unfavorable associations in COAD, BLCA, DLBC and MESO, but favorable associations in READ and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR579 RNA expression.
This table summarizes MIR579 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR579. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR579 shows lower tumor expression in THCA and higher tumor expression in LUAD, LUSC, BLCA, STAD and HNSC. The LUAD box plot shows higher MIR579 RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with MIR579 in patient tissues and cancer cell lines. In patient samples, MIR579 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
